PRIVA-PRAVASTATIN TABLET

البلد: كندا

اللغة: الإنجليزية

المصدر: Health Canada

العنصر النشط:

PRAVASTATIN SODIUM

متاح من:

PHARMAPAR INC

ATC رمز:

C10AA03

INN (الاسم الدولي):

PRAVASTATIN

جرعة:

10MG

الشكل الصيدلاني:

TABLET

تركيب:

PRAVASTATIN SODIUM 10MG

طريقة التعاطي:

ORAL

الوحدات في الحزمة:

100

نوع الوصفة الطبية :

Prescription

المجال العلاجي:

HMG-COA REDUCTASE INHIBITORS

ملخص المنتج:

Active ingredient group (AIG) number: 0122563001; AHFS:

الوضع إذن:

CANCELLED POST MARKET

تاريخ الترخيص:

2022-07-29

خصائص المنتج

_Priva-PRAVASTATIN _
_ _
_Page 1 of 37 _
PRODUCT MONOGRAPH
PR
PRIVA-PRAVASTATIN
Pravastatin Sodium Tablets, USP
10 mg, 20 mg and 40 mg
LIPID METABOLISM REGULATOR
PHARMAPAR INC.
DATE OF PREPARATION:
100-5950, Ch. de la Côte de Liesse
September 1, 2015
Mont-Royal
Qc, H4T 1E2
Control # 186294
_Priva-PRAVASTATIN _
_ _
_Page 2 of 37 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION................................................................
3
SUMMARY PRODUCT INFORMATION
....................................................................................
3
INDICATIONS AND CLINICAL USE
..........................................................................................
3
CONTRAINDICATIONS
...............................................................................................................
5
WARNINGS AND PRECAUTIONS
..............................................................................................
5
ADVERSE REACTIONS
..............................................................................................................
10
DRUG INTERACTIONS
..............................................................................................................
13
DOSAGE AND ADMINISTRATION
..........................................................................................
15
OVERDOSAGE
............................................................................................................................
16
ACTION AND CLINICAL PHARMACOLOGY
........................................................................
16
STORAGE AND STABILITY
......................................................................................................
18
DOSAGE FORMS, COMPOSITION AND PACKAGING
......................................................... 18
PART II: SCIENTIFIC INFORMATION
.....................................................................................
19
PHARMACEUTICAL INFORMATION
......................................................................................
19
C